An Official Website of the United States Government
Company Information:
Name:
EVAS THERAPEUTICS, LLC.
Address:
613 HUNTLEY HEIGHTS DRIVE
BALLWIN, MO 63021-
BALLWIN, MO 63021-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
Yes
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Novel Recombinant Anticoagulant Proteins
Award Year / Program / Phase:
2005 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Tzechein Wun
Award Amount:
$152,652.00
Abstract:
DESCRIPTION (provided by applicant): Phase I: Clot formation in the blood vessel (thrombosis) causes a broad range of serious clinical conditions, such as unstable angina, acute myocardial infarction, ischemic stroke, deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation,… More
Pharmacologic treatment of thromboembolism
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Tzechein Wun
Award Amount:
$167,481.00
Abstract:
DESCRIPTION (provided by applicant): Thromboembolic disorders are major causes of morbidity and mortality in the Western societies. Anticoagulants are pivotal agents in the prevention and treatment of arterial and venous thrombosis. The limitations of curr
ently approved anticoagulant drugs have… More
Novel antithrombotic agents to prevent hemodialysis vascular access failure
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Tze-chein Wun – 636-527-4545
Award Amount:
$1,365,616.00
Abstract:
DESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthetic graft (AVG). Unfortunately, primary failure rates were as high as 60 % at 6 months after AVF… More